JP5202827B2 - 感染予防剤 - Google Patents
感染予防剤 Download PDFInfo
- Publication number
- JP5202827B2 JP5202827B2 JP2006213273A JP2006213273A JP5202827B2 JP 5202827 B2 JP5202827 B2 JP 5202827B2 JP 2006213273 A JP2006213273 A JP 2006213273A JP 2006213273 A JP2006213273 A JP 2006213273A JP 5202827 B2 JP5202827 B2 JP 5202827B2
- Authority
- JP
- Japan
- Prior art keywords
- sphingomyelin
- influenza virus
- infection
- virus infection
- influenza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003449 preventive effect Effects 0.000 title claims description 9
- 208000015181 infectious disease Diseases 0.000 title description 11
- 241000712461 unidentified influenza virus Species 0.000 claims description 30
- 230000009385 viral infection Effects 0.000 claims description 21
- 235000013336 milk Nutrition 0.000 claims description 9
- 210000004080 milk Anatomy 0.000 claims description 9
- 239000008267 milk Substances 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 5
- 150000003904 phospholipids Chemical class 0.000 description 18
- 230000000694 effects Effects 0.000 description 13
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 11
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 11
- 230000003405 preventing effect Effects 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 241000700605 Viruses Species 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000002265 prevention Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 241000712431 Influenza A virus Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 241000713196 Influenza B virus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000001471 micro-filtration Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000020185 raw untreated milk Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- LHEJDBBHZGISGW-UHFFFAOYSA-N 5-fluoro-3-(3-oxo-1h-2-benzofuran-1-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1C2=CC=CC=C2C(=O)O1 LHEJDBBHZGISGW-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 241000285721 Ibaraki virus Species 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 230000020958 lipid digestion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- -1 sphingomyelin Chemical compound 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
一方、抗ウイルス作用をもつ成分(特許文献4)や、ワクチンとして用いる抗原(特許文献5)を乳化させ、リポソームを形成させるための脂質成分としてスフィンゴミエリンを利用する事例は報告されているが、スフィンゴミエリン自体に抗インフルエンザウイルス活性があることは知られていない。また、乳に含まれる糖脂質であるガングリオシドが、抗インフルエンザ活性をもつことは公知(特許文献6)であるが、構成成分であるシアル酸がこの作用に重要であり、シアル酸を含む糖脂質が、ウイルスと粘膜上皮細胞の結合を拮抗的に阻害するメカニズムにより発現される機能である。したがって、シアル酸を含まないスフィンゴミエリンの機能を想起させるものではないことは明白である。
(A型インフルエンザウイルス、B型インフルエンザウイルスに対する感染予防効果の確認)
A型インフルエンザウイルスとしてA/Guinzhouウイルスを、B型インフルエンザウイルスとしてB/Ibarakiウイルスをマウス(Balb/c、雄、6週齢)に経鼻感染させ、同時に実施例1で得られたスフィンゴミエリン(SPM)100μg/ml溶液を5μl/鼻腔内投与量(投与量:0.5μg)で経鼻投与し、インフルエンザウイルスの感染予防効果を鼻腔内洗浄液中のウイルス価で判定した。なお、対照として、それぞれのインフルエンザウイルスを単独経鼻感染した群をおいた。判定にはMDCK細胞を用いたプラーク法を用いた。
(スフィンゴミエリンの経口投与におけるインフルエンザウイルスの感染予防効果の確認。)
インフルエンザウイルスPR8(H1N1)を1×103pfuのウイルス量でマウス(Balb/c、雄、6週齢)に感染させた。感染処理前に、スフィンゴミエリンを経口投与し、その感染予防効果をウイルス感染3日後の鼻腔洗浄液中のウイルス価で判定した。経口投与に当たってはスフィンゴミエリンは水に分散して使用した。判定にはMDCK細胞を用いたプラーク法を用いた。
Claims (1)
- 乳由来のスフィンゴミエリンを有効成分とするインフルエンザウイルス感染予防剤。
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006213273A JP5202827B2 (ja) | 2006-08-04 | 2006-08-04 | 感染予防剤 |
CA2660120A CA2660120C (en) | 2006-08-04 | 2007-08-02 | Agent for preventing infection |
US12/376,251 US20090312291A1 (en) | 2006-08-04 | 2007-08-02 | Agent for preventing infection |
EP07805892A EP2047856A4 (en) | 2006-08-04 | 2007-08-02 | AGENT FOR PREVENTING INFECTION |
CN200780029115.1A CN101505767B (zh) | 2006-08-04 | 2007-08-02 | 预防感染的药剂 |
AU2007279674A AU2007279674B2 (en) | 2006-08-04 | 2007-08-02 | Agent for preventing infection |
PCT/JP2007/065171 WO2008016108A1 (fr) | 2006-08-04 | 2007-08-02 | Agent de prévention d'une infection |
EP11001424.8A EP2335705B1 (en) | 2006-08-04 | 2007-08-02 | Use of sphingomyelin for the treatment of influenza |
KR1020097002329A KR101250323B1 (ko) | 2006-08-04 | 2007-08-02 | 감염 예방제 |
ES11001424.8T ES2444501T3 (es) | 2006-08-04 | 2007-08-02 | Uso de esfingomielina para el tratamiento de la gripe |
US13/544,748 US20120277187A1 (en) | 2006-08-04 | 2012-07-09 | Agent for Preventing Infection |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006213273A JP5202827B2 (ja) | 2006-08-04 | 2006-08-04 | 感染予防剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008037788A JP2008037788A (ja) | 2008-02-21 |
JP5202827B2 true JP5202827B2 (ja) | 2013-06-05 |
Family
ID=39173223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006213273A Active JP5202827B2 (ja) | 2006-08-04 | 2006-08-04 | 感染予防剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP5202827B2 (ja) |
CN (1) | CN101505767B (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE537951C2 (sv) * | 2013-07-01 | 2015-12-01 | Hero Ag | Profylaktisk användning av modersmjölksersättning mot otit |
DE102018217334A1 (de) * | 2018-10-10 | 2020-04-16 | Harbins Ruhr Bioscience, Inc. | Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel |
WO2022015348A1 (en) | 2020-07-16 | 2022-01-20 | Harbins Ruhr Bioscience, Inc. | Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3581010B2 (ja) * | 1998-03-18 | 2004-10-27 | 雪印乳業株式会社 | 脂質の消化吸収機能改善剤 |
JP2001233773A (ja) * | 2000-02-22 | 2001-08-28 | Toko Yakuhin Kogyo Kk | 抗ウイルス剤 |
JP3891536B2 (ja) * | 2000-03-30 | 2007-03-14 | 明治乳業株式会社 | 哺乳動物の乳由来のリン脂質含有経口性組成物 |
CN1190235C (zh) * | 2002-01-19 | 2005-02-23 | 余内逊 | 复方羊胎素保健食品系列制备方法 |
JP2003252765A (ja) * | 2002-02-28 | 2003-09-10 | Snow Brand Milk Prod Co Ltd | 腸管運動機能不全性疾患の治療剤 |
JP2004002215A (ja) * | 2002-05-23 | 2004-01-08 | National Institute Of Advanced Industrial & Technology | スフィンゴ脂質誘導体の製造方法 |
AU2003254202A1 (en) * | 2002-07-30 | 2004-02-16 | Esperion Therapeutics, Inc. | Methods of using non-human animal apoliprotein a-i protein |
JP4210744B2 (ja) * | 2003-02-14 | 2009-01-21 | 独立行政法人産業技術総合研究所 | スフィンゴ脂質誘導体 |
US20080317767A1 (en) * | 2004-04-08 | 2008-12-25 | Tobias Braxmeier | Tripartitle Raftophilic Strutures and their Use |
-
2006
- 2006-08-04 JP JP2006213273A patent/JP5202827B2/ja active Active
-
2007
- 2007-08-02 CN CN200780029115.1A patent/CN101505767B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101505767B (zh) | 2013-01-02 |
JP2008037788A (ja) | 2008-02-21 |
CN101505767A (zh) | 2009-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101390044B1 (ko) | 내장 지방 축적 억제제 및 혈중 아디포넥틴 농도 증가 촉진및/또는 감소 억제제 | |
US20120277187A1 (en) | Agent for Preventing Infection | |
WO2008062559A1 (fr) | Supplément diététique, agent anti-fatigue, activateur d'endurance physique, aliment fonctionnel, ou produit cosmétique | |
KR20210141546A (ko) | 안정한 박테리아 추출물 제조 공정 및 이의 약제로서의 용도 | |
JP5443979B2 (ja) | 新規のロイコトリエン受容体アンタゴニスト | |
TW200916093A (en) | Treating or preventing rotavirus infection | |
JPWO2020009135A1 (ja) | インフルエンザの重症化を抑制するための抗インフルエンザウイルス剤 | |
JP5202827B2 (ja) | 感染予防剤 | |
JP2000007570A (ja) | 抗内分泌障害剤 | |
JP2016535734A (ja) | コリン及びその誘導体を含む組成物、その用途及び調製方法 | |
WO2023282283A1 (ja) | 口腔環境改善用組成物 | |
WO2017221845A1 (ja) | 血流改善剤、ローヤルゼリー組成物及びローヤルゼリー組成物の製造方法 | |
JP2007320900A (ja) | 内臓脂肪蓄積抑制剤及び、血中アディポネクチン濃度増加促進及び/又は減少抑制剤 | |
JP2008037789A (ja) | 感染予防剤 | |
JP7260951B2 (ja) | 膝の痛み改善剤 | |
JP7260952B2 (ja) | 肩の痛み改善剤 | |
JP6346405B2 (ja) | 感染予防剤 | |
JP2008038011A (ja) | 高純度リン脂質の製造法 | |
JP2008214241A (ja) | 免疫調節剤 | |
JP4792561B2 (ja) | ヒト免疫不全ウイルス感染・増殖抑制剤 | |
JP6823397B2 (ja) | 歩行中のつまずき改善剤 | |
JP7077235B2 (ja) | 筋萎縮抑制組成物 | |
US20240197765A1 (en) | Antiviral compositions comprising liposome-encapsulated ascorbyl glucoside and natural extracts | |
JP2003300890A (ja) | 血中トリグリセリド濃度低下剤 | |
JP2018016558A (ja) | 腰痛改善剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090730 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20110706 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120511 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120709 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121212 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130123 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130208 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130213 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5202827 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160222 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |